Pharma Equity Group Issues DKK 8.8M Convertible Loans to Strengthen Capital Structure
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 01 2025
0mins
Source: Globenewswire
- Financing Scale: Pharma Equity Group has decided to issue convertible loans totaling up to DKK 8.8 million, aimed at strengthening the company's capital structure and supporting future growth.
- Repayment Arrangement: This issuance will repay existing convertible loans and a credit facility, ensuring financial stability and reducing debt burden for the company.
- Conversion Terms: The new loans have a conversion price of DKK 0.12 per share, with the conversion right exercisable within 30 days after the 24th month post-loan conclusion, enhancing potential returns for shareholders.
- Strategic Goals: Pharma Equity Group focuses on its subsidiary Reponex Pharmaceuticals' drug candidates, planning to accelerate the development of its medical projects through this financing, ensuring long-term growth.
Get Free Real-Time Notifications for Any Stock
Monitor tickers like PHAR with instant alerts to capture every critical market movement.
Sign up for free to build your custom watchlist and receive professional-grade stock notifications.
Analyst Views on PHAR
Wall Street analysts forecast PHAR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PHAR is 39.50 USD with a low forecast of 37.00 USD and a high forecast of 42.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 20.590
Low
37.00
Averages
39.50
High
42.00
Current: 20.590
Low
37.00
Averages
39.50
High
42.00
About PHAR
Pharming Group NV is a biopharmaceutical company based in the Netherlands. The Company is engaged in the development, production and commercialization of human therapeutic proteins to be used in the therapies. The Company's product portfolio is aimed at treatments for genetic disorders, blood-related disorders, infectious and inflammatory diseases, tissue and bone damage and surgical/traumatic bleeding. Its core product, RUCONEST (conestat alfa) is a recombinant human C1 esterase inhibitor approved for the treatment of acute Hereditary Angioedema (HAE) attacks in patients in Europe, the Unites States, Israel and South Korea. The product is available on a named-patient basis in other territories where it has not yet obtained marketing authorization.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Pharming Reports $376M Preliminary 2025 Revenue, Exceeding Guidance by 27%
- Significant Revenue Growth: Pharming anticipates approximately $376 million in revenue for 2025, exceeding the revised guidance of $365-$375 million by 27%, reflecting strong market demand for RUCONEST and Joenja.
- Strong RUCONEST Performance: RUCONEST generated $231.2 million in revenue during the first nine months of 2025, representing a 34% increase from the previous year, which enhances the company's financial stability in a competitive hereditary angioedema market.
- Rising Demand for Joenja: Joenja contributed $38.4 million in revenue, up 20% year-over-year, indicating successful new drug promotion and increasing acceptance in the U.S. market, which is expected to further drive future revenue growth.
- Positive Future Outlook: Pharming expects continued revenue growth in 2026 and plans to provide detailed updates on its clinical pipeline and financial guidance during the Investor Day on February 3, 2026, demonstrating the company's commitment to long-term value creation.
Continue Reading
Pharming Reports $376 Million Revenue for 2025, Exceeding Guidance by 27%
- Significant Revenue Growth: Pharming's estimated revenue for 2025 is approximately $376 million, exceeding the revised guidance range of $365 to $375 million, reflecting a robust 27% year-over-year growth driven by strong demand for RUCONEST® and Joenja®.
- Commitment to Cost Control: The company expects its operating expenses for 2025 to be within the range of $304 to $308 million, underscoring its commitment to cost discipline, which will enhance overall profitability.
- Advancement of Clinical Pipeline: Pharming plans to provide updates on its clinical pipeline during the Investor Day on February 3, 2026, including leniolisib for primary immunodeficiencies and KL1333 for mitochondrial diseases, demonstrating ongoing efforts in innovative drug development.
- Expert Participation Enhances Confidence: The Investor Day will feature presentations from leading clinical experts discussing the latest insights into immune dysregulation and mitochondrial diseases, boosting investor confidence and expectations for Pharming's future growth.
Continue Reading